Dogwood Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Dogwood Therapeutics şirketinin toplam hissedar öz sermayesi $949.4K ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $2.3M ve $1.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$2.04m
Eşitlik	US$949.43k
Toplam yükümlülükler	US$1.33m
Toplam varlıklar	US$2.28m

Son finansal sağlık güncellemeleri

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Aug 24

Recent updates

Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Jun 25

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Mar 09

Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?

Nov 02

Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Jul 19

Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study

Jun 04

Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans

Mar 31

Virios Therapeutics gains 10% on research deal in irritable bowel syndrome

Feb 01

Virios Therapeutics prices IPO at $10

Dec 17

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: DWTX 'nin kısa vadeli varlıkları ( $2.3M ) kısa vadeli yükümlülüklerini ( $1.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: DWTX un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: DWTX borçsuzdur.

Borcun Azaltılması: DWTX şu anda borcu yok ancak 5 yıl öncesine ait verimiz olmadığı için karşılaştırma yapamıyoruz.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: DWTX şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: DWTX un, serbest nakit akışı her yıl % 10.2 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Dogwood Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Dogwood Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Listing Rule 5550(b)(1)

Nasdaq Grants Exception Till October 28 to Virios Therapeutics to Regain Compliance with Minimum Bid Price Requirement

Virios Therapeutics, Inc. Receives Another Letter from Nasdaq

Virios Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Recent updates

Dogwood Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Listing Rule 5550(b)(1)

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

New major risk - Revenue and earnings growth

Dogwood Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Price target increased by 92% to US$83.33

Virios Therapeutics, Inc. Appoints Angela Walsh as Chief Financial Officer

Virios Therapeutics, Inc. (NasdaqCM:VIRI) acquired Pharmagesic (Holdings) Inc. from Sealbond Limited.

New major risk - Financial position

Virios Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Virios Therapeutics, Inc. Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

New major risk - Revenue and earnings growth

Nasdaq Grants Exception Till October 28 to Virios Therapeutics to Regain Compliance with Minimum Bid Price Requirement

Virios Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million.

New major risk - Shareholder dilution

Virios Therapeutics, Inc. has filed a Follow-on Equity Offering.

Virios Therapeutics, Inc. Receives Another Letter from Nasdaq

Virios Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Virios Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

New major risk - Revenue and earnings growth

Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid

New major risk - Market cap size

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Insufficient new directors

New major risk - Financial position

Virios Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Virios Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

New major risk - Market cap size

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Virios Therapeutics, Inc. Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as A New Treatment Option for Fibromyalgia

Virios Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-Covid Symptoms Following Treatment with A Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?

Virios Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023

Price target decreased to US$2.00

High number of new directors

Virios Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Virios Therapeutics Receives Letter Regarding Bid Price Requirement from the Listing Qualifications Department of the Nasdaq

Virios Therapeutics, Inc. Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia

Virios Therapeutics slides 11% postmarket on proposed stock offering

Virios Therapeutics, Inc. Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial

Virios Therapeutics GAAP EPS of -$0.44 beats by $0.07

Virios Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Virios Therapeutics, Inc.(NasdaqCM:VIRI) dropped from Russell Microcap Value Index

Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Founder & Director recently bought US$59k worth of stock

Virios Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new directors

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Virios Therapeutics Inc. Withdraws its Application for Investigational New Drug (IND 157311)

Virios Therapeutics, Inc. Achieves over 50% Enrollment Milestone in Its Phase 2B Clinical Trial for Fibromyalgia

Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?

Virios Therapeutics Receives New Patent for Antiviral Inhibitor Combination

Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Virios Therapeutics, Inc.(NasdaqCM:VIRI) dropped from Russell Microcap Growth Index

Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with Fibromyalgia

Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study

Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans

Virios Therapeutics, LLC to Report Q4, 2020 Results on Mar 18, 2021

Virios Therapeutics, Inc. Announces Research Collaboration to Explore Role of HSV-1 in Irritable Bowel Syndrome

Virios Therapeutics gains 10% on research deal in irritable bowel syndrome

Virios Therapeutics, LLC has completed an IPO in the amount of $30 million.

Virios Therapeutics prices IPO at $10

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin